# EDGAR Filing Document

**Accession Number:** 0001666306
**File Stem:** 0001062993-25-013262
**Filing Date:** 2025-7
**Character Count:** 18954
**Document Hash:** a9cfb5005c661a7c6c523313ef4aaa44
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001062993-25-013262.hdr.sgml**: 20250729

**ACCESSION NUMBER**: 0001062993-25-013262

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20250725

**FILED AS OF DATE**: 20250729

**DATE AS OF CHANGE**: 20250729

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** CRANDELL KEITH
- **CENTRAL INDEX KEY:** 0001219039

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40502
- **FILM NUMBER:** 251163718

**MAIL ADDRESS:**
- **STREET 1:** 8755 W. HIGGINS ROAD
- **STREET 2:** SUITE 1025
- **CITY:** CHICAGO
- **STATE:** IL
- **ZIP:** 60631
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** NELSEN ROBERT
- **CENTRAL INDEX KEY:** 0001219042

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40502
- **FILM NUMBER:** 251163716

**MAIL ADDRESS:**
- **STREET 1:** 8755 W. HIGGINS ROAD
- **STREET 2:** SUITE 1025
- **CITY:** CHICAGO
- **STATE:** IL
- **ZIP:** 60631
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** BYBEE CLINTON
- **CENTRAL INDEX KEY:** 0001219043

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40502
- **FILM NUMBER:** 251163717

**MAIL ADDRESS:**
- **STREET 1:** 8755 W. HIGGINS ROAD
- **STREET 2:** SUITE 1025
- **CITY:** CHICAGO
- **STATE:** IL
- **ZIP:** 60631
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** ARCH Venture Fund IX, L.P.
- **CENTRAL INDEX KEY:** 0001666306

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40502
- **FILM NUMBER:** 251163720

**BUSINESS ADDRESS:**
- **STREET 1:** 8755 W. HIGGINS ROAD, SUITE 1025
- **CITY:** CHICAGO
- **STATE:** IL
- **ZIP:** 60631
- **BUSINESS PHONE:** 773-380-6600

**MAIL ADDRESS:**
- **STREET 1:** 8755 W. HIGGINS ROAD, SUITE 1025
- **CITY:** CHICAGO
- **STATE:** IL
- **ZIP:** 60631
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** ARCH Venture Fund IX Overage, L.P.
- **CENTRAL INDEX KEY:** 0001666307

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40502
- **FILM NUMBER:** 251163719

**BUSINESS ADDRESS:**
- **STREET 1:** 8725 W. HIGGINS ROAD, SUITE 290
- **CITY:** CHICAGO
- **STATE:** IL
- **ZIP:** 60631
- **BUSINESS PHONE:** 773-380-6600

**MAIL ADDRESS:**
- **STREET 1:** 8725 W. HIGGINS ROAD, SUITE 290
- **CITY:** CHICAGO
- **STATE:** IL
- **ZIP:** 60631
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** ARCH Venture Partners IX Overage, L.P.
- **CENTRAL INDEX KEY:** 0001723172

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40502
- **FILM NUMBER:** 251163721

**BUSINESS ADDRESS:**
- **STREET 1:** 8755 W. HIGGINS ROAD
- **STREET 2:** SUITE 1025
- **CITY:** CHICAGO
- **STATE:** IL
- **ZIP:** 60631
- **BUSINESS PHONE:** 773-380-6600

**MAIL ADDRESS:**
- **STREET 1:** 8755 W. HIGGINS ROAD
- **STREET 2:** SUITE 1025
- **CITY:** CHICAGO
- **STATE:** IL
- **ZIP:** 60631
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** ARCH Venture Partners IX, L.P.
- **CENTRAL INDEX KEY:** 0001723173

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40502
- **FILM NUMBER:** 251163722

**BUSINESS ADDRESS:**
- **STREET 1:** 8755 W. HIGGINS ROAD
- **STREET 2:** SUITE 1025
- **CITY:** CHICAGO
- **STATE:** IL
- **ZIP:** 60631
- **BUSINESS PHONE:** 773-380-6600

**MAIL ADDRESS:**
- **STREET 1:** 8755 W. HIGGINS ROAD
- **STREET 2:** SUITE 1025
- **CITY:** CHICAGO
- **STATE:** IL
- **ZIP:** 60631
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** ARCH Venture Partners IX, LLC
- **CENTRAL INDEX KEY:** 0001723174

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40502
- **FILM NUMBER:** 251163723

**BUSINESS ADDRESS:**
- **STREET 1:** 8755 W. HIGGINS ROAD
- **STREET 2:** SUITE 1025
- **CITY:** CHICAGO
- **STATE:** IL
- **ZIP:** 60631
- **BUSINESS PHONE:** 773-380-6600

**MAIL ADDRESS:**
- **STREET 1:** 8755 W. HIGGINS ROAD
- **STREET 2:** SUITE 1025
- **CITY:** CHICAGO
- **STATE:** IL
- **ZIP:** 60631
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Lyell Immunopharma, Inc.
- **CENTRAL INDEX KEY:** 0001806952
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 833006753
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 201 HASKINS WAY
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** 650 695-0677

**MAIL ADDRESS:**
- **STREET 1:** 201 HASKINS WAY
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>ARCH Venture Partners IX, LLC<br><sub>(Last) (First) (Middle)</sub><br>8755 W. HIGGINS ROAD, SUITE 1025<br><sub>(Street)</sub><br>CHICAGO, IL 60631<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-07-25 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Lyell Immunopharma, Inc. [ LYEL ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>ARCH Venture Partners IX, L.P.<br><sub>(Last) (First) (Middle)</sub><br>8755 W. HIGGINS ROAD, SUITE 1025<br><sub>(Street)</sub><br>CHICAGO, IL 60631<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-07-25 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Lyell Immunopharma, Inc. [ LYEL ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>ARCH Venture Partners IX Overage, L.P.<br><sub>(Last) (First) (Middle)</sub><br>8755 W. HIGGINS ROAD, SUITE 1025<br><sub>(Street)</sub><br>CHICAGO, IL 60631<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-07-25 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Lyell Immunopharma, Inc. [ LYEL ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>ARCH Venture Fund IX, L.P.<br><sub>(Last) (First) (Middle)</sub><br>8755 W. HIGGINS ROAD, SUITE 1025<br><sub>(Street)</sub><br>CHICAGO, IL 60631<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-07-25 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Lyell Immunopharma, Inc. [ LYEL ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>ARCH Venture Fund IX Overage, L.P.<br><sub>(Last) (First) (Middle)</sub><br>8755 W. HIGGINS ROAD, SUITE 1025<br><sub>(Street)</sub><br>CHICAGO, IL 60631<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-07-25 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Lyell Immunopharma, Inc. [ LYEL ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>CRANDELL KEITH<br><sub>(Last) (First) (Middle)</sub><br>C/O ARCH VENTURE PARTNERS IX, LLC<br>8755 W. HIGGINS ROAD, SUITE 1025<br><sub>(Street)</sub><br>CHICAGO, IL 60631<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-07-25 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Lyell Immunopharma, Inc. [ LYEL ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>BYBEE CLINTON<br><sub>(Last) (First) (Middle)</sub><br>C/O ARCH VENTURE PARTNERS IX, LLC<br>8755 W. HIGGINS ROAD, SUITE 1025<br><sub>(Street)</sub><br>CHICAGO, IL 60631<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-07-25 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Lyell Immunopharma, Inc. [ LYEL ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>NELSEN ROBERT<br><sub>(Last) (First) (Middle)</sub><br>8755 W. HIGGINS ROAD, SUITE 1025<br><sub>(Street)</sub><br>CHICAGO, IL 60631<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-07-25 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Lyell Immunopharma, Inc. [ LYEL ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock |  |  |  |  |  |  |  | 910317<sup>(3)</sup> | I | By ARCH Venture Fund IX, L.P.<sup>(1)</sup> |
| Common Stock |  |  |  |  |  |  |  | 910317<sup>(3)</sup> | I | By ARCH Venture Fund IX Overage, L.P.<sup>(2)</sup> |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

---

### Footnotes:

(1) These shares are directly held by ARCH Venture Fund IX, L.P. ("ARCH IX"). ARCH Venture Partners IX, L.P. ("GPLP"), as the sole general partner of ARCH IX, may be deemed to beneficially own the shares held by ARCH IX. ARCH Venture Partners IX, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by ARCH IX. As managing directors of GPLLC, each of Keith Crandell, Robert Nelsen and Clinton Bybee (the "ARCH Managing Directors"), may be deemed to beneficially own the shares held by ARCH IX. Each of GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any.

(2) These shares are directly held by ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"). ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. GPLLC, as the sole general partner of Overage GPLP, may be deemed to beneficially own the shares held by ARCH Overage. As managing directors of GPLLC, each of the ARCH Managing Directors may be deemed to beneficially own the shares held by ARCH Overage. Each of Overage GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any.

(3) The amount of shares reported herein reflects a 1-for-20 reverse stock split that occurred on May 27, 2025.

**Remarks:**
Due to overlapping managing directors, a separate Form 3 was filed for the purchase of common stock of Lyell by ARCH Venture Fund XIII, L.P., and related entities: ARCH Venture Partners XIII, L.P., ARCH Venture Partners XIII, LLC, Steven Gillis, Kristina Burow and Paul Berns.

**Signature:** ARCH Venture Partners IX, LLC, By: /s/ Mark McDonnell, as Attorney-in-Fact for Robert Nelsen, Managing Director  
**Date:** 2025-07-29

**Signature:** ARCH Venture Partners IX, L.P., By: ARCH Venture Partners IX, LLC, its General Partner, By: /s/ Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director  
**Date:** 2025-07-29

**Signature:** ARCH Venture Partners IX Overage, L.P., By: ARCH Venture Partners IX, LLC, its General Partner, By: /s/ Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director  
**Date:** 2025-07-29

**Signature:** ARCH Venture Fund IX, L.P., By: ARCH Venture Partners IX, L.P., its General Partner, By: ARCH Venture Partners IX, LLC, its General Partner, By: /s/ Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director  
**Date:** 2025-07-29

**Signature:** ARCH Venture Fund IX Overage, L.P., By: ARCH Venture Partners IX Overage, L.P., its General Partner, By: ARCH Venture Partners IX, LLC, its General Partner, By: /s/ Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director  
**Date:** 2025-07-29

**Signature:** Keith Crandell, Managing Director, By: /s/ Mark McDonnell, as Attorney-in-Fact  
**Date:** 2025-07-29

**Signature:** Clinton Bybee, Managing Director, By: /s/ Mark McDonnell, as Attorney-in-Fact  
**Date:** 2025-07-29

**Signature:** Robert Nelsen, Managing Director, By: /s/ Mark McDonnell, as Attorney-in-Fact  
**Date:** 2025-07-29

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**